Capacity Expansion Succeeds

The most likely outcome is that Eli Lilly executes the Houston active-ingredient plant largely as planned, reinforcing U.S. supply for Mounjaro, Zepbound and future incretin drugs. The site fits Lilly's post-2020 strategy of reducing bottlenecks and bringing more critical manufacturing capacity inside the United States.

Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.